This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
2 Mar 2011

NeuroPhage Secures $12.4M for Alzheimer's Disease Treatment

NeuroPhage Pharmaceuticals announced that it has secured $12.4 million in Series B financing, which will be mostly directed to the development for the treatment of Alzheimer's disease.

Cambridge, MA-based NeuroPhage Pharmaceuticals has closed $12.4 million in new venture funding to support a Phase I trial of its lead therapy for Alzheimer's disease. Two new investors, MerieuxDeveloppement and Shire, both contributed to the Series B, which brings the fledgling biotech's total venture haul to $19.6 million.

 

The upstart biotech has been working on a "protein disaggregation" platform which was hatched in the lab of Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University. NeuroPhage believes that it

Related News

Recently Visited